Colunbotai Biotech (06990) announced interim results with profit attributable to shareholders of 388 million yuan, turning a year-on-year loss into profit

According to the Zhitong Finance App, Colun Botai Biotech (06990) announced interim results for the six months ended June 30, 2026. The group achieved revenue of 978 million yuan (RMB, same below) during the period, an increase of 2.93%; gross profit of 737 million yuan, an increase of 11.65%; profit attributable to shareholders of 388 million yuan, which turned a loss into a profit; and a basic profit of 1.6639 yuan per share.

According to the announcement, the increase in revenue during the period was mainly due to the increase in drug sales, which contributed 657 million yuan in revenue.